World Journal of Surgery

, Volume 37, Issue 10, pp 2419–2427 | Cite as

Identification of Hepatoma-Derived Growth Factor as a Potential Prognostic and Diagnostic Marker for Extrahepatic Cholangiocarcinoma




Hepatoma-derived growth factor (HDGF) has been reported to play a pivotal role in the development and progression of several tumors. The aim of the present study was to analyze whether HDGF is a potential prognostic and diagnostic marker for extrahepatic cholangiocarcinoma (EHCC).


The immunostaining of HDGF was analyzed by immunohistochemistry for 65 pathologically confirmed EHCC, and its correlation with clinicopathologic factors and prognosis was investigated. Meanwhile, to evaluate the diagnostic value of HDGF, an enzyme-linked immunosorbent assay (ELISA) was performed to measure HDGF levels in the serum samples of 83 EHCC patients and 51 healthy controls.


Positive expression of HDGF was detected in 30 (46.2 %) patients with EHCC and correlated with poor tumor differentiation (P = 0.024). Univariate analysis showed that the positive HDGF expression group had a significantly poorer survival rate than the negative HDGF expression group did (P < 0.001). Multivariate analysis demonstrated that HDGF expression and N stage were independent prognostic factors. The mean serum HDGF level in EHCC patients was 2.39-fold higher than that in healthy controls (P = 0.002). The optimal cut-off value for HDGF was 122.15 pg/mL, providing a sensitivity of 66.27 % and a specificity of 88.24 %. The area under the curve (AUC) of HDGF was 0.807 (95 % confidence interval 0.730–0.870), demonstrating that HDGF was a potential biomarker for EHCC.


HDGF was a valuable independent prognostic factor after curative resection in EHCC, and it provided an important basis for screening/treating high-risk patients. Meanwhile, our study indicated that serum HDGF levels can be used as a noninvasive and potential diagnostic marker for EHCC.



This work was supported by research grants from the Graduate Independent Innovation Foundation of Shandong University (No. yzc10131). We are indebted to Dr. Shuhai Li for excellent statistical work and are also grateful to Drs. Lutao Du and Yi Zhang for their technical assistance.


  1. 1.
    Khan SA, Thomas HC, Davidson BR et al (2005) Cholangiocarcinoma. Lancet 366:1303–1314PubMedCrossRefGoogle Scholar
  2. 2.
    Patel T (2006) Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 3:33–42PubMedCrossRefGoogle Scholar
  3. 3.
    Jarnagin WR, Shoup M (2004) Surgical management of cholangiocarcinoma. Semin Liver Dis 24:189–199PubMedCrossRefGoogle Scholar
  4. 4.
    Nakamura H, Kambe H, Egawa T et al (1989) Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta 183:273–284PubMedCrossRefGoogle Scholar
  5. 5.
    Nakamura H, Izumoto Y, Kambe H et al (1994) Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem 269:25143–25149PubMedGoogle Scholar
  6. 6.
    Everett AD, Lobe DR, Matsumura ME et al (2000) Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 105:567–575PubMedCrossRefGoogle Scholar
  7. 7.
    Kishima Y, Yamamoto H, Izumoto Y et al (2002) Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem 277:10315–10322PubMedCrossRefGoogle Scholar
  8. 8.
    Okuda Y, Nakamura H, Yoshida K et al (2003) Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci 94:1034–1041PubMedCrossRefGoogle Scholar
  9. 9.
    Yoshida K, Nakamura H, Okuda Y et al (2003) Expression of hepatoma-derived growth factor in hepatocarcinogenesis. J Gastroenterol Hepatol 18:1293–1301PubMedCrossRefGoogle Scholar
  10. 10.
    Tsang TY, Tang WY, Tsang WP et al (2009) Mechanistic study on growth suppression and apoptosis induction by targeting hepatoma-derived growth factor in human hepatocellular carcinoma HepG2 cells. Cell Physiol Biochem 24:253–262PubMedCrossRefGoogle Scholar
  11. 11.
    Meng J, Xie W, Cao L et al (2010) shRNA targeting HDGF suppressed cell growth and invasion of squamous cell lung cancer. Acta Biochim Biophys Sin (Shanghai) 42:52–57CrossRefGoogle Scholar
  12. 12.
    Hu TH, Huang CC, Liu LF et al (2003) Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer 98:1444–1456PubMedCrossRefGoogle Scholar
  13. 13.
    Ren H, Tang X, Lee JJ et al (2004) Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol 22:3230–3237PubMedCrossRefGoogle Scholar
  14. 14.
    Uyama H, Tomita Y, Nakamura H et al (2006) Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 12:6043–6048PubMedCrossRefGoogle Scholar
  15. 15.
    Yamamoto S, Tomita Y, Hoshida Y et al (2006) Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 12:117–122PubMedCrossRefGoogle Scholar
  16. 16.
    Yoshida K, Tomita Y, Okuda Y et al (2006) Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 13:159–167PubMedCrossRefGoogle Scholar
  17. 17.
    Yamamoto S, Tomita Y, Hoshida Y et al (2007) Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol 14:2141–2149PubMedCrossRefGoogle Scholar
  18. 18.
    Hu TH, Lin JW, Chen HH et al (2009) The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors. Dis Colon Rectum 52:319–326PubMedCrossRefGoogle Scholar
  19. 19.
    Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257PubMedCrossRefGoogle Scholar
  20. 20.
    Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027PubMedCrossRefGoogle Scholar
  21. 21.
    Mobius C, Demuth C, Aigner T et al (2007) Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. Eur J Surg Oncol 33:1025–1029PubMedCrossRefGoogle Scholar
  22. 22.
    Zhang J, Ren H, Yuan P et al (2006) Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 66:18–23PubMedCrossRefGoogle Scholar
  23. 23.
    Mao J, Xu Z, Fang Y et al (2008) Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci 99:2120–2127PubMedCrossRefGoogle Scholar
  24. 24.
    Lee KH, Choi EY, Kim MK et al (2010) Hepatoma-derived growth factor regulates the bad-mediated apoptotic pathway and induction of vascular endothelial growth factor in stomach cancer cells. Oncol Res 19:67–76PubMedCrossRefGoogle Scholar
  25. 25.
    Ooi BN, Mukhopadhyay A, Masilamani J et al (2010) Hepatoma-derived growth factor and its role in keloid pathogenesis. J Cell Mol Med 14:1328–1337PubMedCrossRefGoogle Scholar
  26. 26.
    Liu YF, Zhao R, Guo S et al (2011) Expression and clinical significance of hepatoma-derived growth factor as a prognostic factor in human hilar cholangiocarcinoma. Ann Surg Oncol 18:872–879PubMedCrossRefGoogle Scholar
  27. 27.
    Zhang A, Long W, Guo Z et al (2010) Development and clinical evaluation of a multi-purpose mAb and a sandwich ELISA test for hepatoma-derived growth factor in lung cancer patients. J Immunol Methods 355:61–67PubMedCrossRefGoogle Scholar
  28. 28.
    Weidner N, Semple JP, Welch WR et al (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1–8PubMedCrossRefGoogle Scholar
  29. 29.
    Ren H, Chu Z, Mao L (2009) Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther 8:1106–1112PubMedCrossRefGoogle Scholar
  30. 30.
    Yu Y, Shen H, Yu H et al (2011) Systematic proteomic analysis of human hepotacellular carcinoma cells reveals molecular pathways and networks involved in metastasis. Mol Biosyst 7:1908–1916PubMedCrossRefGoogle Scholar
  31. 31.
    Patel AH, Harnois DM, Klee GG et al (2000) The utility of CA 19–9 in the diagnosis of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95:204–207PubMedCrossRefGoogle Scholar
  32. 32.
    Akdogan M, Sasmaz N, Kayhan B et al (2001) Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori 87:337–339PubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2013

Authors and Affiliations

  1. 1.Department of NursingBinzhou Vocational CollegeBinzhouPeople’s Republic of China
  2. 2.Department of Hepatobiliary SurgeryQilu Hospital, Shandong UniversityJinanPeople’s Republic of China

Personalised recommendations